LifeVantage Co. (NASDAQ:LFVN – Get Free Report)’s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $6.64 and traded as high as $8.57. LifeVantage shares last traded at $8.35, with a volume of 77,470 shares traded.
LifeVantage Price Performance
The stock has a market capitalization of $106.05 million, a P/E ratio of 29.82 and a beta of 0.81. The stock has a 50 day moving average price of $6.97 and a 200-day moving average price of $6.64.
LifeVantage (NASDAQ:LFVN – Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $0.21 earnings per share (EPS) for the quarter. LifeVantage had a return on equity of 27.02% and a net margin of 1.75%. The business had revenue of $48.25 million for the quarter.
Institutional Investors Weigh In On LifeVantage
About LifeVantage
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
Read More
- Five stocks we like better than LifeVantage
- Stock Dividend Cuts Happen Are You Ready?
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- What Are the FAANG Stocks and Are They Good Investments?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- What Is WallStreetBets and What Stocks Are They Targeting?
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.